Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Jan;300(1):3-9.
doi: 10.1007/s00403-007-0813-2. Epub 2007 Nov 6.

Development of outcome measures for autoimmune dermatoses

Elizabeth Gaines  1 , Victoria P Werth
Affiliations
Review

Development of outcome measures for autoimmune dermatoses

Elizabeth Gaines et al. Arch Dermatol Res. 2008 Jan.

Abstract

Validated outcome measures are essential in monitoring disease severity. Specifically in dermatology, which relies heavily on the clinical evaluation of the patient and not on laboratory values and radiographic tests, outcome measures help standardize patient care. Validated cutaneous scoring systems, much like standardized laboratory values, facilitate disease management and follow therapeutic response. Several cutaneous autoimmune dermatoses, specifically cutaneous lupus erythematosus (CLE), dermatomyositis (DM), and pemphigus vulgaris (PV), lack such outcome measures. As a result, evaluation of disease severity and patients' response to therapy over time is less reliable. Ultimately, patient care is compromised. These diseases, which are often chronic and relapsing and remitting, are also often refractory to treatment. Without outcome measures, new therapies cannot be systematically assessed in these diseases. Clinical trials that are completed without standardized outcome measures produce less reliable results. Therefore, the development of validated outcome measures in these autoimmune dermatoses is critical. However, the process of developing these tools is as important, if not more so, than their availability. This review examines the steps that should be considered when developing outcome measures, while further examining their importance in clinical practice and trials. Finally, this review more closely looks at CLE, DM, and PV and addresses the recent and ongoing progress that has been made in the development of their outcome measures.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Cutaneous LE disease area and severity index (CLASI)
See this image and copyright information in PMC

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PMC', 'value': 'PMC3928016', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3928016/'}, {'type': 'PubMed', 'value': '16297185', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16297185/'}]}
    2. Albrecht J, Taylor L, Berlin J et al (2005) The CLASI (cutaneous lupus erythematosus disease area severity and index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 125:889–894 - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.1529-8019.2007.00117.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.1529-8019.2007.00117.x'}, {'type': 'PubMed', 'value': '17537137', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/17537137/'}]}
    2. Albrecht J, Werth VP (2007) Development of the CLASI as an outcome instrument in cutaneous lupus erythematosus. Dermatol Ther 20:93–101 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1001/archderm.142.11.1447', 'is_inner': False, 'url': 'https://doi.org/10.1001/archderm.142.11.1447'}, {'type': 'PubMed', 'value': '17116835', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/17116835/'}]}
    2. Beissert S, Werfel T, Frieling U, Bohm M, Sticherling M, Stadler R, Zillikens D, Rzany B, Hunzelmann N, Meurer M, Gollnick H, Ruzicka T, Pillekamp H, Junghans V, Luger TA (2006) A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 142(11):1447–1454 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1002/art.1780350606', 'is_inner': False, 'url': 'https://doi.org/10.1002/art.1780350606'}, {'type': 'PubMed', 'value': '1599520', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/1599520/'}]}
    2. Bombaridier C, Gladmann DD, Urowitz MB et al (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studied in SLE. Arthritis Rheum 35(6):630–640 - PubMed
    1. Bonilla-Martinez Z, Albrecht J, Taylor L, Okawa J, Dulay S, Werth V (2007) The CLASI is a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol (in press) - PMC - PubMed